Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SIGN (SIGN) 24-Hour Volatility at 45.3%: Whale Accumulation and Surging Trading Volume Trigger Sharp Fluctuations

SIGN (SIGN) 24-Hour Volatility at 45.3%: Whale Accumulation and Surging Trading Volume Trigger Sharp Fluctuations

Bitget PulseBitget Pulse2026/04/16 14:09
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, SIGN's price surged from a high of $0.0299 to a low of $0.02058 and is currently at $0.02075, with an amplitude of 45.3%, showing a pattern of rising first and then sharply falling. The 24-hour trading volume increased significantly; according to CoinMarketCap, it was about $52.97 million, with some platforms peaking at $235 million.

Analysis of Abnormal Fluctuations

- Whale accumulation: Newly activated wallets withdrew over 12 million SIGN (worth approximately $336,000) from Binance in a short period, which occurred near the 1-Day order block support level.

- Trading volume and price spike: On Binance spot market, SIGN/USDT experienced a 3.31% price spike with a trading volume of 112,000 SIGN, and overall 24-hour trading activity increased.

Market View and Outlook

Community sentiment is cautiously optimistic, with traders posting several long SIGN position signals, such as entries at $0.0315-0.0325 and targets set at $0.037-0.050, viewing a breakout above $0.0340 as a rebound confirmation. Some opinions caution about supply concentration (76.9% held by a single multi-signature) and heightened exchange inflows, but acknowledge the deep liquidity ($291 million) and short squeeze potential from negative funding rates. Volatility may persist in the short term, with attention on order block support and breakout signals.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational reference only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23